- Home
- QNCX vs HHS Comparison
QNCX vs HHS Comparison
Compare QNCX & HHS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QNCX
- HHS
- Stock Information
- Founded
- QNCX 2012
- HHS 1923
- Country
- QNCX United States
- HHS United States
- Employees
- QNCX N/A
- HHS N/A
- Industry
- QNCX Biotechnology: Biological Products (No Diagnostic Substances)
- HHS Advertising
- Sector
- QNCX Health Care
- HHS Consumer Discretionary
- Exchange
- QNCX Nasdaq
- HHS Nasdaq
- Market Cap
- QNCX 44.0M
- HHS 37.0M
- IPO Year
- QNCX 2019
- HHS N/A
- Fundamental
- Price
- QNCX $1.02
- HHS $4.51
- Analyst Decision
- QNCX Strong Buy
- HHS
- Analyst Count
- QNCX 5
- HHS 0
- Target Price
- QNCX $8.00
- HHS N/A
- AVG Volume (30 Days)
- QNCX 511.8K
- HHS 20.1K
- Earning Date
- QNCX 05-16-2025
- HHS 05-16-2025
- Dividend Yield
- QNCX N/A
- HHS N/A
- EPS Growth
- QNCX N/A
- HHS N/A
- EPS
- QNCX N/A
- HHS N/A
- Revenue
- QNCX N/A
- HHS $185,242,000.00
- Revenue This Year
- QNCX N/A
- HHS $6.54
- Revenue Next Year
- QNCX N/A
- HHS N/A
- P/E Ratio
- QNCX N/A
- HHS N/A
- Revenue Growth
- QNCX N/A
- HHS N/A
- 52 Week Low
- QNCX $0.51
- HHS $4.27
- 52 Week High
- QNCX $2.45
- HHS $8.87
- Technical
- Relative Strength Index (RSI)
- QNCX 38.15
- HHS 45.63
- Support Level
- QNCX $0.98
- HHS $4.77
- Resistance Level
- QNCX $1.16
- HHS $4.81
- Average True Range (ATR)
- QNCX 0.09
- HHS 0.32
- MACD
- QNCX 0.00
- HHS -0.02
- Stochastic Oscillator
- QNCX 20.04
- HHS 21.79
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.
About HHS Harte-Hanks Inc.
Harte-Hanks Inc is a customer experience company. The Company operates three business segments: Marketing Services; Customer Care; and Fulfillment & Logistics Services. The company has a geographic presence in the United States and Other countries. The majority of the revenue is earned from the United States.